Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Debt-to-Equity : -0.29 (As of Sep. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Eloxx Pharmaceuticals Debt-to-Equity?

Eloxx Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $3.13 Mil. Eloxx Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.62 Mil. Eloxx Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-20.05 Mil. Eloxx Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2023 was -0.29.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eloxx Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ELOX' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.69 Med: 0.38 Max: 7.42
Current: -0.29

During the past 13 years, the highest Debt-to-Equity Ratio of Eloxx Pharmaceuticals was 7.42. The lowest was -2.69. And the median was 0.38.

ELOX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs ELOX: -0.29

Eloxx Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Eloxx Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eloxx Pharmaceuticals Debt-to-Equity Chart

Eloxx Pharmaceuticals Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.44

1.18

0.60

-1.26

Eloxx Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															-2.69	-1.26	-0.38	-0.33	-0.29

Competitive Comparison of Eloxx Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Eloxx Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eloxx Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's Debt-to-Equity falls into.

Eloxx Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eloxx Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.692	+	8.692)	/	-10.66
	=	-1.26

Eloxx Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.134	+	2.624)	/	-20.048
	=	-0.29

Eloxx Pharmaceuticals (OTCPK:ELOX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eloxx Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Watertown, MA, USA, 02472

Website

https://www.eloxxpharma.com

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.

Executives

Sumit Aggarwal	director, officer: PRESIDENT AND CEO	480 ARSENAL WAY, WATERTOWN MA 02472
Vijay Modur	officer: HEAD OF R&D	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451
Lindsay Androski	director	C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Gadi Veinrib	director	12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Jasbir Seehra	director	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Zafrira Avnur	director	210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467
Alan Edmund Walts	director	197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129
Daniel E. Geffken	officer: Chief Financial Officer	DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Pontifax Iv Gp L.p.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax Management 4 G.p. (2015) Ltd.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (israel) Iv, L.p.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (china) Iv L.p.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (cayman) Iv L.p.	10 percent owner	4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum	director	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404